Medicine and Dentistry
Percutaneous Aortic Valve Replacement
100%
Meta-Analysis
87%
Revascularization
47%
Acute Coronary Syndrome
42%
Drug-Eluting Stent
39%
Percutaneous Coronary Intervention
37%
Apoplexy
35%
Myocardial Infarction
33%
Cardiovascular System
28%
Randomized Clinical Trial
28%
Primary Percutaneous Coronary Intervention
26%
Disease
23%
Stent Thrombosis
22%
Coronary Artery Disease
22%
Aortic Stenosis
22%
All Cause Mortality
20%
Aortic Valve
18%
Saphenous Vein Graft
18%
Odds Ratio
18%
Thrombosis
18%
Ischemia
17%
ST Elevation
16%
Randomized Controlled Trial
16%
Hospital Mortality
16%
Aortic Valve Replacement
16%
Glycoprotein IIb/IIIa Inhibitors
15%
Invasive Procedure
14%
Women's Health
14%
Nonsteroid Antiinflammatory Agent
14%
Thrombus Aspiration
14%
Rapamycin
14%
Cardiovascular Disease
13%
Hemodynamic
13%
Unstable Angina Pectoris
13%
ST Segment Elevation Myocardial Infarction
12%
Systematic Review
12%
Health Care Cost
12%
Hazard Ratio
12%
Veterans Affairs
11%
Intravascular Ultrasound
10%
Aortic Insufficiency
10%
Clinical Trial
10%
Cardiac Catheterization
10%
Restenosis
9%
Echocardiography
9%
Ischemic Heart Disease
9%
Heart Failure
9%
Acute Heart Infarction
9%
Cardiovascular Risk
8%
Acute Kidney Injury
8%
Keyphrases
Meta-analysis
87%
Confidence Interval
68%
Randomized Trial
64%
Risk Ratio
51%
Transcatheter Aortic Valve Replacement
50%
Drug-eluting Stent
31%
Acute Coronary Syndrome
30%
Aspirin
29%
Myocardial Infarction
29%
Odds Ratio
27%
All-cause Mortality
27%
Stent Thrombosis
27%
Bare Metal Stent
24%
Randomized Clinical Trial
24%
Primary Percutaneous Coronary Intervention
21%
Revascularization
21%
ST-elevation Myocardial Infarction (STEMI)
20%
Percutaneous Coronary Intervention
18%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
18%
Coronary Artery Disease
17%
Cardiovascular Outcomes
15%
Randomized Controlled Trial
15%
Saphenous Vein Graft
14%
Early Invasive Strategy
14%
Clinical Outcomes
13%
Cardiovascular Risk
12%
Hypertensive Patients
11%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
11%
Glycoprotein IIb/IIIa Inhibitors
11%
Invasive Therapy
11%
Cardiovascular Prevention
10%
Culprit-only Revascularization
10%
Updated Meta-analysis
10%
Surgical Aortic Valve Replacement
10%
Women's Health Initiative
10%
Coronary Artery Bypass Grafting
10%
Long-term Mortality
10%
Aspiration Thrombectomy
10%
Drug Use
10%
Peri-procedural
10%
Verapamil
10%
Trandolapril
10%
Stent
10%
Patients with Coronary Artery Disease
10%
Restenosis
9%
Placebo
9%
Invasive Strategy
9%
Major Bleeding
9%
Percutaneous Intervention
9%
Stable Angina
9%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Infarction
64%
Coronary Artery Disease
45%
Acute Coronary Syndrome
45%
All Cause Mortality
38%
Randomized Controlled Trial
38%
Stent Thrombosis
30%
ST Segment Elevation Myocardial Infarction
26%
Acetylsalicylic Acid
24%
Placebo
23%
Fibrinogen Receptor
20%
Cardiovascular Disease
20%
Non-Steroidal Anti-Inflammatory Drug
18%
Randomized Clinical Trial
17%
Bleeding
17%
Trandolapril
17%
Unstable Angina Pectoris
16%
Major Adverse Cardiac Event
16%
Verapamil
16%
Heart Failure
15%
Hospital Mortality
15%
Disease
14%
Acute Heart Infarction
14%
Ischemia
13%
Heart Muscle Ischemia
12%
Clinical Trial
12%
Aortic Stenosis
12%
Statin (Protein)
12%
Atrial Fibrillation
12%
Thrombosis
12%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
Prevalence
10%
Paclitaxel
10%
Rapamycin
10%
Non ST Segment Elevation Myocardial Infarction
10%
Clopidogrel
9%
Diabetes Mellitus
8%
Combination Therapy
8%
Cardiovascular Mortality
8%
Paravalvular Leak
8%
Cardiogenic Shock
8%
Acute Kidney Failure
8%
Restenosis
8%
Atherosclerosis
7%
Ischemic Heart Disease
7%
Fibrinolytic Agent
7%
Thienopyridine
7%
Syndrome
7%
Heparin
7%
Cause of Death
6%
Endocrine Therapy
6%
